APG

Ascentage Pharma is a global integrated biopharmaceutical company focused on discovering, developing, and commercializing therapies for hematologic malignancies and other cancers. The company is best known for building an apoptosis-focused pipeline that targets key cell-death pathways such as B-cell lymphoma 2 and the mouse double minute 2 homolog-p53 axis. Its portfolio includes the marketed BCR-ABL inhibitor olverembatinib and the marketed B-cell lymphoma 2 inhibitor lisaftoclax in China, alongside additional clinical-stage small-molecule oncology assets including alrizomadlin, APG-2449, APG-5918, and APG-3288. Ascentage operates across discovery, clinical development, manufacturing, and commercialization, with operations in China and the United States. The company is publicly traded in Hong Kong and on Nasdaq.